Friday, 16 October 2026European Markets

Energy Stock Plummets 29% In Recent Sessions: Is It Time To Sell?

Loading stream...

(VIANEWS) - NEW SOURCES ENERGY (NSE.AS) took another hit on Monday as its shares plummeted by 29.41% over 21 sessions, from EUR0.04 to EUR0.03 as of 15:08 EST - continuing two consecutive days of losses for the company and with four straight sessions of decline on its listing AEX-Index; after four straight losses NSE.AS' closing price of EUR0.03 represents 51.54% less than its 52-week high of EUR0.07.

About NEW SOURCES ENERGY

New Sources Energy N.V., previously known as Management Share NV, is a renewable energy company based out of Amersfoort in the Netherlands that specializes in developing, operating and investing in projects which generate electricity using renewable sources. Operating since July 2011 under its current name.

Yearly Analysis

At its current stock price of EUR0.03, NEW SOURCES ENERGY appears to be trading below its 52-week high of EUR0.07. This suggests it has underperformed, although it remains well above its 52-week low of EUR0.01, suggesting it has shown some improvement recently. Investors should remember that past performance does not always indicate future outcomes, and conduct their own analysis to ascertain if a stock is suitable for investment. Additional factors, including its financial health, industry outlook and competitive landscape should also be taken into account before making decisions regarding investments.

Technical Analysis

Stock Analysis for NEW SOURCES ENERGY(NSE) has experienced an unexpected rise in stock prices recently, reaching EUR0.09 at present - higher than both its 50-day and 200-day moving averages of EUR0.02 and EUR0.05, respectively. It seems to indicate a strong upward trend in its value; however, today's trading volume of 2500 is 92.88% below its average volume of 113919. Low trading volume may signal a lack of interest, leading to greater volatility. NSE experienced negative 9.13% volatility last week, negative 3.03% for the last month and 14.59% positive quarter volatility. In the last week, average volatility reached its highest amplitude: 25.79%; in the last month: 15.555% and in the last quarter : 14.59 %. Fluctuations in volatility could be taken as an indication of uncertainty within the market and should be treated with caution. According to stochastic oscillator analysis, NSE stocks currently appear overbought (>=80). Investors should keep a close watch on NSE's low trading volume and high volatility as potential indicators of market uncertainty. An overbought status as determined by the stochastic oscillator could also serve as a warning sign, signaling to be wary or take profits before further investing. Stock prices can be affected by many different factors and should be assessed in light of broader market trends. Although NSE has experienced an upward trend recently, investors should still exercise caution and closely track its performance, particularly during periods when its stock is performing particularly well.

Equity Analysis

Negative return on equity of -288.52% indicates that a company has experienced losses over the past twelve months and is not generating profits for shareholders. This should serve as a clear signal to potential investors that this firm might not be sustainable and provide returns to them in the form of sustainable operations or returns for their investments. Investors should remain wary about a company's ability to generate positive returns on equity in the future. A firm with a longstanding history of negative returns may have financial or operational issues which need addressing before becoming profitable again. Before investing in any company, it is critical to evaluate their financial statements, operational performance and competitive position thoroughly in order to assess whether it can turn its financial fortunes around and bring positive returns back for investors.

More news about NEW SOURCES ENERGY (NSE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com